

Mechanism-based Inactivation by Aromatization of the Transaminase BioA Involved in Biotin Biosynthesis in *Mycobacterium tuberculosis*

Ce Shi,[†] Todd W. Geders,[‡] Sae Woong Park,[§] Daniel J. Wilson,[†] Helena I. Boshoff,^{||} Orishadipe Abayomi,^{||,‡} Clifton E. Barry, III,^{||} Dirk Schnappinger,[§] Barry C. Finzel,[‡] and Courtney C. Aldrich^{*,†}

[†]Center for Drug Design, Academic Health Center, University of Minnesota, Minnesota 55455, United States


[‡]Department of Medicinal Chemistry, University of Minnesota, Minnesota 55455, United States

[§]Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States

^{||}Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, United States

S Supporting Information

ABSTRACT: BioA catalyzes the second step of biotin biosynthesis, and this enzyme represents a potential target to develop new anti-tubercular agents. Herein we report the design, synthesis, and biochemical characterization of a mechanism-based inhibitor (**1**) featuring a 3,6-dihydropyrid-2-one heterocycle that covalently modifies the pyridoxal 5'-phosphate (PLP) cofactor of BioA through aromatization. The structure of the PLP adduct was confirmed by MS/MS and X-ray crystallography at 1.94 Å resolution. Inactivation of BioA by **1** was time- and concentration-dependent and protected by substrate. We used a conditional knock-down mutant of *M. tuberculosis* to demonstrate the antitubercular activity of **1** correlated with BioA expression, and these results provide support for the designed mechanism of action.



INTRODUCTION

Mycobacterium tuberculosis (*Mtb*), the etiological agent of tuberculosis (TB), has plagued mankind for millennia and is presently the leading cause of bacterial infectious disease mortality.¹ Rifampin, the last approved first-line drug for TB chemotherapy was introduced in 1968.² During the last four decades resistance to all of the first- and second-line antitubercular agents has been reported. Consequently, new drugs that inhibit novel targets in *Mtb* are needed. Biotin (vitamin H) is an essential cofactor responsible for activation of carbon dioxide in acyl-CoA carboxylases (ACCs) involved in fatty acid metabolism and pyruvate carboxylase (PCC) in gluconeogenesis.³ Biotin starvation of an *Mtb* biotin auxotroph led to cell death, suggesting that biotin biosynthesis represents a very attractive pathway for development of new antitubercular agents.⁴ Significantly, conditional silencing of *bioA*, which encodes for the second enzyme in the biotin biosynthetic pathway, after establishment of an infection, demonstrated that BioA is essential to maintain a chronic infection in a murine model of TB.⁵

In analogy to the well-studied pathway in *E. coli*, biotin biosynthesis in *Mtb* begins from pimeloyl-CoA, which is elaborated to biotin in four steps catalyzed, respectively by BioF, BioA, BioD, and BioB (Scheme 1).⁶ The first step is carried out by BioF that converts pimeloyl-CoA to 7-keto-8-aminopelargonic acid (KAPA) through decarboxylative condensation with L-alanine.^{6a} In the second step, BioA, a pyridoxal 5'-phosphate (PLP) dependent enzyme, catalyzes the transamination of KAPA into

7,8-diaminopelargonic acid (DAPA) using S-adenosylmethionine (SAM) as the amino donor.^{6b-d} BioD, dethiobiotin synthetase, carboxylates DAPA to form the imidazolidin-2-one ring of dethiobiotin (DTB) in the third step.^{4a} Finally, BioB, an iron-sulfur cluster enzyme, catalyzes the C-H activation and insertion of sulfur in DTB to afford biotin.^{6e,f} Although the source of pimelate in *Mtb* is unknown, Cronan and co-workers have recently shown that *E. coli* co-opts the fatty acid synthase type II pathway along with BioC (*Mtb* ortholog: Rv0089) and BioH (*Mtb* ortholog: Rv2715) for synthesis of pimeloyl-ACP, which is proposed as the physiologically relevant substrate for BioF.⁷

Amiclenomycin (ACM) isolated from *Streptomyces lavendulae* subsp. *amiclenomycini* and its simplified amino-alcohol analogue ACM-OH are potent inhibitors of BioA, and we have shown that ACM-OH possesses better whole cell activity against *Mtb* (Figure 1).^{8,10c} Synthetic studies indicated the stereochemistry of the 1,4-cyclohexadiene ring is *cis* rather than *trans* as originally assigned.⁹ Amiclenomycin is a mechanism-based inhibitor through covalent modification of the PLP cofactor of BioA via aromatization.¹⁰ Remarkably, ACM exhibits selective antitubercular activity among 40 bacterial strains evaluated.^{8b} Chemical complementation of *Mtb* cultures with DAPA, but not KAPA, antagonizes the activity of ACM, thus confirming the mechanism of action.^{8b} Although amiclenomycin has served as an excellent

Received: May 2, 2011

Published: October 11, 2011


Scheme 1. Biosynthesis of Biotin in *Mtb*

Figure 1. Structure of ampiclenomycin (ACM), ACM-OH, and dihydropyrid-2-one inhibitors 1 and 2.





Figure 2. Proposed aromatization mechanism of 1. Transamination of 1 with enzyme-bound PLP 3 affords the substrate PLP aldimine 4. Subsequent 1,3-prototropic shift via 5 mediated by Lys283 provides ketimine 6. Tautomerization of 6 to 7 is irreversible and leads to formation of a stable PLP adduct.

tool compound, it suffers from poor chemical stability due to spontaneous aromatization.¹⁰

Inspired by the unique aromatization mechanism of inhibition by ampiclenomycin¹⁰ and the extensive previous work by Silverman and co-workers¹¹ on related PLP-dependent mechanism-based inhibitors, we hypothesized that the introduction of a heteroatom into the 1,4-cyclohexadiene ring scaffold would decrease the aromatic stabilization energy and correspondingly would improve the chemical stability of the inhibitor while maintaining the same aromatization mechanism of inhibition (Figure 2). Therefore, a pair of enantiomeric inhibitors based on the simplified ACM-OH structure, containing the 3,6-dihydropyridone heterocycle, was designed to test our hypothesis (Figure 1). Herein, we report the synthesis and kinetic character-

Scheme 2. Synthesis of 1



ization of a mechanism-based inhibitor of BioA with improved chemical stability.

RESULTS

Synthesis of Inhibitors 1 and 2. The enantioselective syntheses of 1 and 2 were accomplished in a convergent fashion employing allylic amine 12 and vinylglycine 13 building blocks as depicted in Scheme 2. The allylic amine (*R*)-12, with high enantiopurity, was efficiently prepared starting with pentynol 8, which was converted to propargylic alcohol 9 by sequential silylation with TBSCl and addition to *para*-formaldehyde. Red-Al mediated reduction of 9 furnished exclusively the *trans*-allylic alcohol and treatment with trichloroacetimidate 10. Asymmetric Overman rearrangement of 10 employing the cationic Pd(II)-catalyst [(*R*)-COP-Cl]₂ provided the trichloroacetyl protected allylic amine (*R*)-11 in 93% yield and 96:4 enantiomeric ratio (*er*).¹² Subsequent deprotection with DIBAL-H yielded the desired allylic amine (*R*)-12. Due to the facile isomerization as well as racemization of vinylglycine derivatives under conventional peptide coupling conditions, we employed DEPBT as the coupling reagent and NaHCO₃ as base, a very mild condition proven to minimize racemization,¹⁴ for the coupling of vinylglycine (*S*)-13^{13a,b} with (*R*)-12 to afford diene 14 in 71% yield. A variety of ring closing metathesis (RCM) catalysts were screened for the RCM reaction of 14, and Hoveyda-Grubbs-II catalyst¹⁵ was found to be most effective, furnishing (3*S*,6*R*)-dihydropyridone 15 in 83% yield. Finally, the desired (3*S*,6*R*)-dihydropyridone 1 was obtained by sequential deprotection of the TBS and Boc groups with HF·Py and HCl-dioxane, respectively. (3*R*,6*S*)-Dihydropyridone 2 was prepared analogously in 10 steps employing [(*S*)-COP-Cl]₂ and (*R*)-13.^{13c} Dihydropyridones 1 and 2 showed substantially improved chemical stability compared to ACM, displaying no




Figure 3. (A) Residual activity of BioA as measured by initial velocity, v , versus preincubation time in the presence of increasing concentrations of **1**, showing time dependent inactivation of BioA. (B) Plot of the observed rate of inactivation constants (k_{obs}) versus the concentration of **1**, from which the kinetic parameters k_{inact} , K_I and the second-order rate constant k_{inact}/K_I were determined. (C) Scheme showing two-step mechanism of inactivation of BioA by **1**.

Table 1. Kinetic Parameters for Inhibition of BioA by ACM and Analogues

| Inhibitor | k_{inact} (min^{-1}) | K_I (μM) | k_{inact}/K_I ($\text{M}^{-1} \text{min}^{-1}$) |
|---------------------|--|-------------------------|--|
| 1 | 0.18 ± 0.01 | 520 ± 72 | $(3.5 \pm 0.5) \times 10^2$ |
| 2 | <0.01 | >2000 | <5 |
| ACM ^a | 0.35 ± 0.05 | 12 ± 2 | $(2.9 \pm 0.6) \times 10^4$ |
| ACM-OH ^a | 0.56 ± 0.05 | 20 ± 2 | $(2.8 \pm 0.4) \times 10^4$ |

^a Reference 6c.

degradation after 60 days at room temperature under aerobic conditions in DMSO as measured by ^1H NMR.

Biochemical Evaluation. The ability of **1** and **2** to irreversibly inhibit BioA was evaluated by preincubation of 0.03–1 mM inhibitor with 2 μM BioA in the absence of substrates (KAPA and SAM). Aliquots were removed at time t and assayed for enzyme activity using a coupled assay employing BioD that measures production of DTB from (S)-KAPA.¹⁰ Dihydropyridone **1** exhibited time-dependent inhibition while **2** displayed no activity. Fitting the observed initial velocity as a function of incubation time t for **1** provided the pseudo first-order rate constants of inactivation, k_{obs} at a given inhibitor concentration $[I]$ (Figure 3A and B). The hyperbolic relationship between k_{obs} and $[I]$ is consistent with a two-step mechanism of inactivation (Figure 3C). The kinetic parameters k_{inact} , K_I (Table 1) were determined from fitting the k_{obs} versus $[I]$ data to eq 2 (see Experimental Section).¹⁷ While the k_{inact} of **1** compares favorably with ACM and ACM-OH, the K_I is approximately 26-fold higher than ACM-OH. The second-order rate constant for inactivation k_{inact}/K_I of **1** is $346 \text{ M}^{-1} \text{min}^{-1}$, which is 80-fold lower than ACM-OH. We also showed that addition of the substrate (S)-KAPA to the initial incubation mixture of BioA and **1** protected against inactivation as expected for a mechanism-based inhibitor. To evaluate potential biochemical selectivity, **1** was also evaluated against two commercially available mammalian PLP-dependent enzymes including alanine aminotransferase and aspartate aminotransferase. Inhibitor **1** was inactive against aspartate aminotransferase, but did show time-dependent inhibition against alanine aminotransferase. The inhibition was not saturable with up to 2 mM **1**; however, the slope of the k_{obs} versus $[I]$ could be




Figure 4. Observed fragments by MS/MS of the m/z 400 ion.




Figure 5. Final $2F_o - F_c$ electron density contoured at 1.0σ for the (A) prereaction complex and (B) postreaction complex.

fit by linear regression analysis to provide the k_{inact}/K_I value of $37 \text{ M}^{-1} \text{min}^{-1}$.

MS analysis. To confirm the formation of the aromatic adduct proposed in Figure 2, MS analysis was performed to identify the formation of the aromatic adduct. We incubated **1** with BioA (360 μM **1**, 26 μM BioA, 50 mM Tris pH 8.0, 10 mM 2-mercaptoethanol and 100 μM PLP) at 37 $^\circ\text{C}$ for 2 h, which led to complete enzyme inactivation. BioA was subsequently isolated by gel filtration to remove excess **1** and PLP, then analyzed using electrospray ionization tandem mass spectrometry. The PLP-adduct **7** was found to dissociate from the protein complex and the quasimolecular ion was detected at m/z 400, which corresponds to the expected aromatized PLP adduct (Figure 4). The MS/MS spectrum of this ion displayed two fragment ions at m/z 302 $[\text{M} + \text{H} - 98]^+$ and 169 $[\text{M} + \text{H} - 231]^+$. The peak at m/z 302 corresponds to the loss of $\text{H}_3\text{O}_3\text{PO}^-$ from the parent molecule suggesting structure **16** while the peak at m/z 169 is consistent with the aromatized inhibitor ion **17** (Figure 4). These results demonstrate formation of the aromatic PLP-adduct and hence provide strong support for the proposed aromatization mechanism.

Structural Characterization. To provide structural insight on adduct formation in the context of the protein active site, we soaked yellow, PLP-loaded crystals of BioA^{4a} with **1** and observed **1** concentrate rapidly to within the crystal affording red crystals before apparently reacting to yield colorless crystals (Figure S2, Supporting Information). Crystals soaked with **1** were frozen in liquid nitrogen when visibly red or colorless. Diffraction data to 1.95 and 1.94 \AA resolution were collected from a red, prereaction crystal and a colorless, postreaction crystal, respectively (Table S1, Supporting Information).

In the prereaction complex, the electron density describes a well-defined PLP covalently bound to Lys283 in a manner identical to previous reports⁴ (Figure 5A). New positive difference density accumulated adjacent to PLP, presumably




Figure 6. Anti-TB activity of **1**. *Mtb bioA*-TetON-1 was grown in biotin-free Sauton's medium containing 0 ng/mL or 10 ng/mL ATC and the indicated concentration of compound **1**. Growth was measured as optical density at 580 nm and normalized to growth without **1**. Error bars represent the standard error of the mean of triplicate measurements.

due to the binding of **1** during soaking (Figure S3, Supporting Information). In the postreaction complex, Lys283 is very clearly no longer covalently bound to PLP and the planar electron density is consistent with the aromatized adduct **7** (Figure 5B, Figure S4B, Supporting Information). The observed adduct possesses small differences in conformation between the two crystallographically unique molecules in the BioA dimer. In the second molecule in the asymmetric unit, electron density for the aromatized adduct is less well-defined and positioned on the opposite side of a flipped Trp64 (Figure S4, Supporting Information). Nevertheless, degradation of the internal aldimine appears complete in both molecules in the postreaction structure.

In vivo Antitubercular Activity. Lastly, we evaluated the antitubercular activity of **1** in biotin-free medium against a mutant strain of *M. tuberculosis* H37Rv termed *Mtb bioA*-TetON-1 that enables conditional expression of BioA.⁵ In the presence of 10 ng/mL anhydrotetracycline (ATC), this strain overexpresses BioA, whereas in the absence of ATC, this strain expresses approximately 7% BioA compared to wt *Mtb*. Overexpression of BioA conferred resistance to **1** while underexpression of BioA restored sensitivity (Figure 6). The correlation between antitubercular activity of **1** and BioA expression level provides support for the designed mechanism of action. Additionally, the active enantiomer **1** was evaluated against two mammalian cell lines (Vero and CHO-K1) to provide an initial assessment of potential toxicity and **1** showed no inhibition of cell viability up to 1 mM, the maximum concentration employed.

DISCUSSION

Rationale and Design of 1. The 1,4-cyclohexadiene warhead of amicenomycin (ACM) is both thermodynamically and kinetically unstable due to the large aromatic stabilization energy of approximately 36 kcal/mol. Replacement of one of the olefins in ACM with an amide isostere provides a 3,6-dihydropyridone heterocycle, which has an estimated aromatic stabilization of only 25 kcal/mol,²⁸ and hence is predicted to be substantially more stable. Mann and Ploux reported on the synthesis of the simplified ACM analog that we term ACM-OH wherein the

polar amino acid moiety on the C-4 side-chain was replaced with a simple neutral hydroxy group.^{6c} We independently synthesized ACM-OH and demonstrated that this structural simplification did not adversely impact antitubercular activity.^{10c} Consequently, we elected to use this modification in our designed 3,6-dihydropyridone analogs. Although the X-ray structure of BioA from *Mtb* was reported,^{4a} simple molecular docking studies were unable to reveal whether **1** or **2** would be more active, thus both enantiomers were prepared.

Antitubercular Activity. Park and co-workers recently developed *Mtb* conditionally regulated knockdown strains of BioA.⁵ Significantly, it was shown that BioA activity must be reduced by approximately 99% to prevent bacterial growth.⁵ It should be noted that these were among the first experiments to address the extent of inactivation, or vulnerability, required to halt replication against any target in *Mtb*. Based on these results, BioA is not particularly vulnerable to inhibition since nearly complete inactivation is required. Consequently, irreversible inhibitors or tight-binding inhibitors with slow dissociation rates are likely to be more effective than simple rapidly reversible inhibitors.²⁹

The *Mtb* strains that enable conditional BioA expression as shown herein are also extremely useful to assess on-target activity of compounds, since these permit the correlation of antitubercular activity with enzyme expression levels. In the present case, overexpression of BioA in strain *Mtb bioA*-TetON-1 renders *Mtb* resistant to **1**, presumably by stoichiometric titration of the inhibitor. This result is readily reconciled, since the amount of BioA produced in this conditional strain is approximately 100-fold greater in the presence of the small molecule anhydrotetracycline (ATC), versus in its absence.

Biochemical Activity and Mechanism. The k_{inact} values for **1** is only 3-fold lower than ACM-OH showing that replacement of the 1,4-cyclohexadiene warhead with the dihydropyridone has little impact on the rate of inactivation. Other described mechanism-based inhibitors of PLP dependent enzymes are typically on the order of $\sim 1 \text{ min}^{-1}$.¹¹ The slow rate of inactivation is commensurate with the relatively slow turnover rate of PLP-dependent enzyme due to slow transamination between the internal and external aldimines.³⁰

Mechanism-based inhibitors of PLP-dependent enzymes that operate through an aromatization mechanism are fascinating and have examples beyond amicenomycin and 3,6-dihydropyridone **1**, including the natural product gabaculine, isogabaculine, 4-amino-4,5-dihydro-2-furancarboxylic acid, 4-amino-4,5-dihydro-2-thiophenecarboxylic acid, D-cycloserine, and gostatin.^{11,34} Interestingly, D-cycloserine is a second-line antitubercular agent, whose mechanism of action is due to irreversible inactivation of the mycobacterial PLP-dependent enzyme D-alanine racemase.² D-Cycloserine has also been shown to inhibit host PLP-dependent enzymes including γ -aminobutyric acid aminotransferase (GABA-AT)^{11a} and serine palmitoyltransferase.³² To investigate the potential selectivity of **1** toward other PLP-dependent enzymes we screened it against porcine alanine aminotransaminase and aspartate aminotransaminase. 3,6-Dihydropyridone **1** was inactive against aspartate aminotransaminase but showed weak time-dependent, yet nonsaturable inhibition against alanine aminotransaminase with a $k_{\text{inact}}/K_{\text{I}}$ value of $37 \text{ M}^{-1} \text{ min}^{-1}$ demonstrating a promising level of biochemical selectivity for BioA.

Several mechanisms of BioA inactivation are plausible including an aromatization mechanism, an enamine mechanism and a Michael addition mechanism.³¹ However, the isolation of the PMP adduct **7** by mass spectrometry and X-ray analysis provides

unequivocal support of the aromatization mechanism of inhibition. Interestingly, inactivation of GABA-AT by 4-amino-4,5-dihydro-2-furancarboxylic acid does not operate through an aromatization mechanism, but rather a Michael-addition mechanism. The resulting adduct between GABA-AT and 4-amino-4,5-dihydro-2-furancarboxylic acid is not stable and undergoes slow hydrolysis resulting in restoration of enzyme activity. By contrast, the corresponding thiophene derivative 4-amino-4,5-dihydro-2-thiophenecarboxylic acid inactivates GABA-AT via an aromatization mechanism and the resulting adduct is stable. The divergence in the mechanisms of these two structurally related inhibitors has been reconciled by consideration of the lower aromatic stabilization energy of furan (16 kcal/mol) relative to thiophene (29 kcal/mol).³³ As noted earlier, the aromatic stabilization of **1** is 25 kcal/mol,²⁸ which appears to be a perfect balance ensuring improved chemical stability of the inhibitor, yet adequate to favor reaction via an aromatization pathway.

Structural Characterization. Consistent with the mass spectrometry results, the crystal structure clearly shows the formation of an adduct of **1** with PLP that is consistent with the proposed structure **7** (Figure 5). Lys283 is positioned to mediate the 1,3-prototropic shift (Figure 2). This adduct is conformationally flexible and possesses few hydrogen bonds to the surrounding protein, which likely explains the discontinuous electron density for the length of the adduct (Figure 5B, Supplemental Figure 3B, Supporting Information). The adduct forms in a time- and concentration-dependent manner with diffraction data collected from intermediate time points showing a mixture of pre- and postreaction states (data not shown). The initial red color observed upon soaking crystals of BioA with **1** likely corresponds to a minor, transient build-up of intermediate **5** (Figure 2).

CONCLUSION

In conclusion, we have designed, synthesized and kinetically and structurally characterized a mechanism-based inhibitor of BioA. The dihydropyrid-2-one heterocycle of **1** is an isostere of the 1,4-cyclohexadiene warhead of ampicillin (ACM) and we demonstrated that it irreversibly inactivates the PLP cofactor of BioA via an aromatization mechanism. The process is highly selective as the enantiomeric inhibitor **2** is completely inactive. We expect the greater chemical stability of **1** compensates for the attenuated inhibitor efficiency relative to ACM as measured by the second order rate constant $k_{\text{inact}}/K_{\text{I}}$. The inverse relationship between antitubercular activity of **1** and BioA protein expression provides support for the designed mechanism of action. In view of the importance of drug-target residence time to efficacy of new drugs, selective mechanism-based inhibitors such as these may have a higher likelihood of translating into useful therapeutics.²⁹ The postreaction complex structure will be used to guide the generation of derivative compounds that will possess higher specificity and activity.

EXPERIMENTAL SECTION

General Methods. All chemical reactions were performed under an inert atmosphere of dry Ar or N₂ in oven-dried (150 °C) glassware. ¹H and ¹³C NMR spectra were recorded on a Varian 600 MHz spectrometer. Proton chemical shifts are reported in ppm from an internal standard of residual chloroform (7.26 ppm) or methanol (3.31 ppm), and carbon chemical shifts are reported using an internal standard of residual chloroform (77.0 ppm) or methanol (49.1 ppm). Proton chemical data are reported as follows: chemical shift, multiplicity (s =

singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br = broad), integration, coupling constant. Melting points were measured on a Büchi S35 melting point apparatus and uncorrected. High resolution mass spectra were obtained on an Agilent TOF II TOF/MS instrument equipped with either an ESI or APCI interface. TLC analyses were performed on TLC silica gel 60F254 from EMD Chemical Inc., and were visualized with UV light, iodine chamber, 10% sulfuric acid or 10% PMA solution. Optical rotations values were obtained on a Rudolph Autopol III Polarimeter. Purifications were performed by flash chromatography on silica gel (Dynamic Adsorbents, 60A). Enzymatic activity, kinetic parameters, and inhibition assays were performed on a molecular devices (Sunnyvale, CA) M5e multimode plate reader. ESI MS/MS experiments were performed on a 2000 QTRAP LC/MS/MS spectrometer (Applied Biosystems).

Materials. Chemicals and solvents were purchased from Sigma-Aldrich Company or Acros Organic Fischer Company, and were used as received. An anhydrous solvent dispensing system (J. C. Meyer) using 2 packed columns of neutral alumina was used for drying THF, Et₂O, and CH₂Cl₂ while 2 packed columns of molecular sieves were used to dry DMF and the solvents were dispensed under argon. (*S*)-*N*-Boc-vinylglycine **13**,^{13a,b} (*R*)-*N*-Boc-vinylglycine **en-an-13**,^{13c} (8*S*)-7-keto-8-aminopelargonic acid hydrochloride salt (KAPA·HCl)¹⁶ and fluorescein-tagged dethiobiotin (FI-DTB)¹⁶ were synthesized according to the reported procedures. BioA and BioD were cloned, overexpressed, and purified following the reported protocols.¹⁶ For crystallization, the published purification protocols were altered to replace Tris and DTT with HEPES and TCEP, respectively.^{4a}

Chemistry Experimental Procedures for Inhibitor 1. *tert*-Butyldimethyl(*pent-4-yn-1-yl*)silane (**S1**). To a solution of pent-4-yn-1-ol **8** (8.4 g, 100 mmol, 1.0 equiv) and imidazole (10.2 g, 150 mmol, 1.5 equiv) in THF (200 mL) at 0 °C was added TBSCl (16.6 g, 110 mmol, 1.1 equiv) portionwise. The reaction was gradually warmed from 0 to 25 °C over 0.5 h and stirred for 2 h at 25 °C. The reaction was quenched by addition of saturated aqueous NH₄Cl (100 mL), and the aqueous layer was separated and extracted with Et₂O (3 × 50 mL). The combined organic layers were washed with saturated aqueous NaCl (50 mL), dried (MgSO₄), and concentrated to afford the crude product as colorless oil. Distillation under reduced pressure afforded the title compound (18.8 g, 95%) as a colorless oil: bp 63–65 °C (P = 10 mbar); ¹H NMR (600 MHz, CDCl₃) δ 0.01 (s, 6H), 0.85 (s, 9H), 1.63 (p, J = 7.0 Hz, 2H), 1.81 (t, J = 2.7 Hz, 1H), 2.22 (td, J = 7.0, 2.7 Hz, 2H), 3.64 (t, J = 6.0 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃) δ -5.4, 15.2, 18.5, 26.2, 30.9, 62.2, 68.3, 84.0. All data are consistent with reported values.¹⁸

6-(*tert*-Butyldimethylsilyloxy)hex-2-yn-1-ol (**9**). To a solution of **S1** (1.98 g, 10 mmol, 1.0 equiv) in THF (50 mL) at -78 °C was added *n*-BuLi (4.8 mL, 2.5 M in hexanes, 12 mmol, 1.2 equiv) dropwise over 15 min. The solution was stirred at -78 °C for 30 min then paraformaldehyde (1.5 g, 50 mmol, 5.0 equiv) was added portionwise over 1 h. The mixture was gradually warmed up to 25 °C and stirred 16 h. The reaction was quenched by addition of saturated aqueous NH₄Cl solution (50 mL) and the aqueous layer was separated and extracted with Et₂O (3 × 25 mL). The combined organic layers were washed with saturated aqueous NaCl (50 mL), dried (MgSO₄) and concentrated. Purification by flash chromatograph afforded the title compound (2.01 g, 88%) as colorless liquid: R_f 0.30 (15% EtOAc/hexanes); ¹H NMR (600 MHz, CDCl₃) δ 0.03 (s, 6H), 0.87 (s, 9H), 1.68 (p, J = 6.0 Hz, 2H), 2.12 (br t, J = 6.0 Hz, 1H), 2.27 (tt, J = 6.0, 2.4 Hz, 2H), 3.66 (t, J = 6.0 Hz, 2H), 4.21 (t, J = 2.4 Hz, 2H); ¹³C NMR (150 MHz, CDCl₃) δ -5.1, 15.4, 18.5, 26.1, 31.8, 51.4, 61.8, 78.7, 86.1. All data are consistent with reported values.¹⁸

(*E*)-5-(*tert*-Butyldimethylsilyloxy)pent-2-en-1-ol (**S2**). To a solution of **9** (1.14 g, 5 mmol, 1.0 equiv) in Et₂O (50 mL) at 0 °C was added Red-Al (3.75 mL, 65 wt % in toluene, 12.5 mmol, 2.5 equiv) dropwise over 20 min. The solution was warmed to 23 °C over 1 h, then stirred 6 h at

23 °C. The reaction was cooled down to 0 °C and quenched by the dropwise addition of MeOH (0.5 mL). The reaction mixture was then diluted with Rochelle's salt solution (50 mL) and stirred for 30 min at 23 °C. The aqueous layer was separated and extracted with Et₂O (3 × 25 mL). The combined organic layers were washed with saturated aqueous NaCl (25 mL), dried (MgSO₄) and concentrated. Purification by flash chromatograph afforded the title compound (1.00 g, 87%) as a colorless oil: *R*_f 0.25 (15% EtOAc/hexanes); ¹H NMR (600 MHz, CDCl₃) δ 0.05 (s, 6H), 0.88 (s, 9H), 1.56 (p, *J* = 6.0 Hz, 2H), 2.07 (q, *J* = 6.6 Hz, 2H), 3.56 (t, *J* = 6.6 Hz, 2H), 4.05 (d, *J* = 3.5 Hz, 2H), 5.50–5.75 (m, 2H); ¹³C NMR (150 MHz, CDCl₃) δ –5.1, 18.3, 25.9, 28.5, 32.2, 62.5, 63.5, 129.5, 133.5. All data are consistent with reported values.⁹

(*E*)-6-(*tert*-Butyldimethylsilyloxy)hex-2-en-1-yl 2,2,2-Trichloroacetimidate (**10**). To a solution of **S2** (920 mg, 4 mmol, 1.0 equiv) in CH₂Cl₂ (20 mL) at 0 °C, DBU (0.72 mL, 4.8 mmol, 1.2 equiv) and CCl₃CN (0.6 mL, 6 mmol, 1.5 equiv) were sequentially added dropwise. The reaction was stirred 10 min at 0 °C then warmed to 23 °C and stirred for 2 h. The reaction was concentrated in vacuo and directly purified by flash chromatograph to afford the title compound (1.42 g, 95%) as colorless oil: *R*_f 0.70 (10% EtOAc/hexanes); ¹H NMR (600 MHz, CDCl₃) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.63 (p, *J* = 6.9 Hz, 2H), 2.14 (td, *J* = 6.9, 6.6 Hz, 2H), 3.62 (t, *J* = 6.9 Hz, 2H), 4.73 (d, *J* = 6.6 Hz, 2H), 5.68 (td, *J* = 15.0, 6.6 Hz, 1H), 5.88 (td, *J* = 15.0, 6.6 Hz, 1H), 8.26 (br s, 1H); ¹³C NMR (150 MHz, CDCl₃) δ –5.05, 18.5, 26.2, 28.8, 32.1, 62.6, 70.1, 91.8, 123.5, 136.7, 162.8; HRMS (ESI+): calcd for C₁₄H₂₇Cl₃NO₂Si [M + H]⁺ 374.0871, found 374.0859 (error 3.2 ppm).

(*R*)-*N*-[6-(*tert*-Butyldimethylsilyloxy)hex-1-en-3-yl]-2,2,2-trichloroacetamide (**11**). To a solution of **10** (1.12 g, 3 mmol, 1.0 equiv) in CH₂Cl₂ (15 mL) at 23 °C was added [(*R*)-COP-Cl]₂ (219 mg, 0.15 mmol, 0.05 equiv). The reaction was stirred at 38 °C for 36 h, then cooled to 23 °C and concentrated in vacuo. Purification by flash chromatograph afforded the title compound (1.04 g, 93%) as light yellow oil: *R*_f 0.66 (10% EtOAc/hexane); [α]_D²³ = –5.0 (c 0.5, CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.55–1.59 (m, 2H), 1.61–1.69 (m, 1H), 1.73–1.79 (m, 1H), 3.61–3.67 (m, 2H), 4.43 (dt, *J* = 13.8, 6.9 Hz, 1H), 5.18 (d, *J* = 10.8 Hz, 1H), 5.23 (d, *J* = 17.4 Hz, 1H), 5.80 (ddd, *J* = 17.4, 10.8, 6.9 Hz, 1H), 6.66 (br d, *J* = 6.0 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃) δ –5.3, 18.3, 25.9, 28.7, 30.8, 53.3, 62.3, 92.9, 116.0, 136.6, 161.2; HRMS (ESI–): calcd for C₁₄H₂₅Cl₃NO₂Si [M – H][–] 372.0726, found 372.0734 (error 2.2 ppm).

(*R*)-6-(*tert*-Butyldimethylsilyloxy)hex-1-en-3-amine (**12**). To a solution of **11** (935 mg, 2.5 mmol, 1.0 equiv) in toluene (10 mL) at –78 °C, was added a solution of DIBAL-H (12.5 mL, 1 M in toluene, 12.5 mmol, 5 equiv) over 15 min. The solution was stirred for 1 h at –78 °C, then quenched with MeOH (0.5 mL). Next, EtOAc (25 mL) and Rochelle's salt solution (25 mL) were added and the reaction mixture was stirred at 23 °C for 30 min. The aqueous layer was separated and extracted with EtOAc (3 × 10 mL). The combined organic extracts were washed with saturated aqueous NaCl (30 mL), dried (MgSO₄) and concentrated. Purification by flash chromatograph afforded the title compound (384 mg, 67%) as colorless oil: *R*_f 0.15 (10% MeOH/CH₂Cl₂); [α]_D²³ = –13.2 (c 0.4, CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.56–1.61 (m, 2H), 1.71–1.76 (m, 2H), 3.56–3.64 (m, 3H), 5.26 (d, *J* = 10.2 Hz, 1H), 5.36 (d, *J* = 17.4 Hz, 1H), 5.84 (ddd, *J* = 17.4, 12.5, 10.2 Hz, 1H); ¹³C NMR (150 MHz, CDCl₃) δ –5.31, 18.3, 26.0, 28.7, 31.0, 54.4, 62.5, 118.6, 136.2; HRMS (ESI+): calcd for C₁₂H₂₈NOSi [M + H]⁺ 230.1935, found 230.1941 (error 2.6 ppm).

tert-Butyl ((*S*)-1-[(*R*)-6-(*tert*-Butyldimethylsilyloxy)hex-1-en-3-yl]amino)-1-oxobut-3-en-2-yl)carbamate (**14**). To a solution of **12** (687 mg, 3.0 mmol, 1.0 equiv) and (*S*)-*N*-Boc-vinylglycine **13**³ (600 mg, 3.0 mmol, 1.0 equiv) in THF (20 mL) at 0 °C, was added NaHCO₃ (756 mg, 9.0 mmol, 3.0 equiv) and DEPT (2.69 g, 9.0 mmol, 3.0 equiv) sequentially. The mixture was stirred at 0 °C for 1 h then warmed to 23 °C and stirred an additional 48 h. The reaction was cooled down to 0 °C and

quenched by the addition of saturated NH₄Cl aqueous solution (20 mL). The aqueous layer was separated and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with saturated aqueous NaCl (30 mL), dried (MgSO₄) and concentrated. Purification by flash chromatograph afforded the title compound (877 mg, 71%) as a colorless oil: *R*_f 0.60 (40% EtOAc/hexanes); [α]_D²³ = –7.5 (c 3.2, CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃) δ 0.03 (s, 6H), 0.88 (s, 9H), 1.44 (s, 9H), 1.45–1.58 (br m, 3H), 1.61–1.67 (br m, 1H), 3.60 (br d, *J* = 4.8 Hz, 2H), 4.44 (br s, 1H), 4.61 (br s, 1H), 5.11 (d, *J* = 9.6 Hz, 1H), 5.14 (d, *J* = 16.8 Hz, 1H), 5.28 (d, *J* = 9.6 Hz, 1H), 5.36 (br s, 1H), 5.39 (br s, 1H), 5.71–5.77 (m, 1H), 5.83–5.88 (m, 1H), 5.89–5.97 (m, 1H); ¹³C NMR (150 MHz, CDCl₃) δ –5.3, 18.3, 25.9, 28.3, 28.9, 31.2, 51.4, 57.3, 62.5, 80.1, 115.3, 118.2, 134.3, 137.9, 155.4, 169.2; HRMS (APCI+): calcd for C₂₁H₄₁N₂O₄Si [M + H]⁺ 413.2830, found 413.2847 (error 4.1 ppm).

tert-Butyl {3-(*S*,6*R*)-6-[3-(*tert*-Butyldimethylsilyloxy)propyl]-2-oxo-3,6-dihydro-pyridin-3-nonyl}carbamate (**15**). To a solution of diene **14** (82.4 mg, 0.20 mmol, 1.0 equiv) in CH₂Cl₂ (20 mL) at 23 °C was added the Hoveyda-Grubbs-II catalyst (6.2 mg, 0.01 mmol, 0.05 equiv). The solution was then stirred at reflux for 12 h. The reaction was cooled to room temperature and concentrated in vacuo. Purification by flash chromatography afforded the title compound (63.7 mg, 83%) as a brown solid: *R*_f 0.30 (50% EtOAc/hexane); mp 108–109.5 °C; [α]_D²³ = +23.2 (c 0.4, CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃) δ 0.04 (s, 3H), 0.05 (s, 3H), 0.88 (s, 9H), 1.45 (s, 9H), 1.55–1.63 (m, 3H), 1.66–1.68 (m, 1H), 3.62–3.65 (m, 2H), 4.08 (br s, 1H), 4.59 (br s, 1H), 5.29 (br s, 1H), 5.72 (d, *J* = 12 Hz, 1H), 5.93 (d, *J* = 12 Hz, 1H), 6.65 (br s, 1H); ¹³C NMR (150 MHz, CDCl₃) δ –5.39, –5.37, 18.3, 25.9, 28.0, 28.3, 32.5, 49.1, 52.8, 62.5, 79.8, 126.8, 126.9, 155.9, 168.7; HRMS (APCI+): calcd for C₁₉H₃₇N₂O₄Si [M + H]⁺ 385.2517, found 385.2518 (error 0.3 ppm).

tert-Butyl [(3*S*,6*R*)-6-(3-Hydroxypropyl)-2-oxo-3,6-dihydropyridin-3-nonyl]carbamate (**53**). To a solution of **15** (57.6 mg, 0.15 mmol) in THF (5 mL) at 0 °C was added HF·Py solution (0.5 mL) dropwise over 10 min and the reaction mixture stirred at 0 °C for an additional 1.5 h. The solution was diluted with EtOAc (20 mL) and saturated aqueous NaHCO₃ (10 mL) was added slowly to neutralize the mixture. The aqueous layer was separated and extracted with EtOAc (3 × 10 mL). The combined organic extracts were washed with saturated aqueous NaCl (30 mL), dried (MgSO₄) and concentrated. Purification by flash chromatograph afforded the title compound (30.3 mg, 75%) as colorless oil: *R*_f 0.30 (10% MeOH/CH₂Cl₂); [α]_D²³ = +8.0 (c 0.8, CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃) δ 1.46 (s, 9H), 1.63–1.67 (m, 3H), 1.77–1.83 (m, 1H), 2.17 (br s, 1H), 3.68 (br s, 2H), 4.12 (br s, 1H), 4.60 (br s, 1H), 5.35 (br s, 1H), 5.73 (d, *J* = 12 Hz, 1H), 5.93 (d, *J* = 12 Hz, 1H), 6.98 (br s, 1H); ¹³C NMR (150 MHz, CDCl₃) δ 27.5, 28.3, 32.1, 48.8, 52.9, 61.9, 79.9, 126.3, 127.1, 156.0, 169.4; HRMS (APCI+): calcd for C₁₃H₂₃N₂O₄ [M + H]⁺ 271.1652, found 271.1649 (error 1.1 ppm).

(3*S*,6*R*)-3-Amino-6-(3-hydroxypropyl)-3,6-dihydropyridin-2(3*H*)-one Hydrochloride Salt (**1**). A solution of HCl in dioxane (1.5 mL, 3 M) was added to **S3** (54 mg, 0.2 mmol) at 0 °C and the solution stirred for 1 h at 0 °C, then the reaction was concentrated in vacuo. Recrystallization with 1:20 EtOH/Et₂O (6 mL) afforded the title compound (37 mg, 88%) as an off-white solid: mp 182–183.5 °C; [α]_D²³ = –32 (c 0.5, MeOH); ¹H NMR (600 MHz, CD₃OD) δ 1.55–1.63 (m, 2H), 1.77–1.81 (m, 2H), 3.58–3.62 (m, 2H), 4.24 (br s, 1H), 4.43 (br s, 1H), 5.93 (dt, *J* = 10.8, 2.4 Hz, 1H), 6.14 (dt, *J* = 10.8, 2.4 Hz, 1H); ¹³C NMR (150 MHz, CD₃OD) δ 28.4, 32.6, 54.7, 62.6, 70.1, 120.7, 133.1, 166.8; HRMS (ESI+): calcd for C₈H₁₃N₂O₂ [M + H]⁺ 171.1128, found 171.1124 (error 2.3 ppm).

Anti-TB activities in BioA-suppressed Mtb Mutant (bioA-TetON-1). *Mtb* bioA-TetON-1 was grown at 37 °C in Sauton's medium containing 1 μM biotin to an OD₅₈₀ of 0.2 to 0.4, harvested by centrifugation, washed twice with biotin-free Sauton's medium, and diluted in fresh biotin-free Sauton's medium to an OD₅₈₀ of ~0.07. 50 μL of the

bacterial culture were used to inoculate 96-well plates and 150 μL of compound **1** were added to give final concentrations of 500 to 1.95 mM using 2-fold serial dilutions. When added, anhydrotetracycline (ATC) was used at a concentration of 10 ng/mL. Wells containing no compound **1** were used as controls. 96-well plates were incubated in a humidified incubator at 37 $^{\circ}\text{C}$. Optical densities were measured after 6 to 28 days.

Coupled Continuous Assay to Evaluate the Time-dependent Inhibition of BioA. *A. Assay Procedure.* BioA (2 μM) was combined with compound **1** (0–1 mM) in 2 \times reaction buffer (200 mM bicine pH 8.6, 100 mM NaHCO_3 , 2 mM MgCl_2 , 0.005% Igepal CA-630, 10 mM ATP, 200 μM PLP) at 0, 10, 15, 20, 25, and 27.5 min, which correspond to preincubation times of 30, 20, 15, 10, 5, and 2.5 min. At 30 min, 2.5 μL of these BioA–1 incubation mixtures were added to 47.5 μL of a reaction solution, resulting in a final concentration of 100 nM BioA, 320 nM BioD, 12.5 μM KAPA, 20 nM Fl-DTB, 185 nM streptavidin, 1 mM TCEP, 1 mM SAM in 1 \times reaction buffer in duplicate. Addition of the substrates KAPA and SAM at these concentrations was shown to prevent measurable binding of **1** or **2** to BioA over the time period used to analyze the data. Reactions were read in a 384 well black plate (Corning #3575) using an excitation of 485 nm, emission at 530 nm and cutoff also at 530 nm. The initial velocities were determined as the time to produce 70 nM dethiobiotin.

B. Data Processing. Inhibitor **1** showed time dependent inhibition of BioA while **2** was not active under the assay condition. The residual activity curve for **1** shown in Figure 3A, which describes the initial velocity, v_i as a function of preincubation time, t_i was fit to eq 1 by nonlinear regression analysis using Graphpad Prism 4.0 to obtain values for k_{obs} at each inhibitor concentration:

$$[P] = v_i e^{-k_{\text{obs}} t} \quad (1)$$

where P is the concentration of product formed at time t . The secondary plot of k_{obs} as a function of inhibitor concentration, $[I]$, was fit to eq 2 to provide values for k_{inact} and K_i by nonlinear regression analysis using Graphpad Prism 4.0.

$$k_{\text{obs}} = \frac{k_{\text{inact}}}{1 + K_i/[I]} \quad (2)$$

MS/MS Analysis of PLP-inhibitor Adduct. *A. Sample Preparation.* A solution of inhibitor 400 μM **1**, 26 μM BioA, 50 mM Tris–HCl (pH 8.0), 10 mM 2-mercaptoethanol and 100 μM PLP was incubated at 37 $^{\circ}\text{C}$ for 2 h in a total volume of 100 μL . Excess inhibitor and PLP were removed by gel-filtration chromatography on a Zeba desalting column (Thermo Fisher). The columns were washed 3 times with 300 μL 1 mM Tris–HCl buffer pH 7.5, after which 100 μL of the reaction mixture was applied to the column and eluted by centrifugation. The purified protein solution was diluted 10-fold with deionized H_2O .

B. MS Procedure and Data Analysis. Enzyme samples were introduced into the ESI source by infusion with a syringe pump (120 $\mu\text{L}/\text{h}$). Optimal ESI conditions (source temperature 250 $^{\circ}\text{C}$; drying gas (N_2) flow rate 7 mL/min; nebulizing gas 7 psi; capillary voltage 400 V; capillary offset 70 V; skimmer 27 V; octopole RF 120 Vpp) were based on similar studies by Mann et al.^{10b} For MS/MS experiments, the observed quasimolecular molecular ion at m/z 400.4 was selected and a collision energy of 40 was applied. The resulting MS/MS spectrum is shown in Figure S2 (Supporting Information).

Structural Characterization of BioA·1 Complex. *Crystallization of BioA.* Yellow crystals of BioA were grown within 24–48 h at 20 $^{\circ}\text{C}$ by microseeding in hanging drops using the vapor diffusion method. Crystals were obtained by mixing 2.0 μL of 10 mg mL^{-1} protein solution (25 mM HEPES pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.1 mM TCEP), 2.0 μL of microseed-containing reservoir solution (8–12% PEG 8000, 100 mM MgCl_2 , 100 mM HEPES pH 7.5). For the prereaction

complex, red crystals were obtained by soaking the yellow, PLP-loaded crystals in reservoir solution containing 15% PEG 400 and 10 mM **1** for 5 s before freezing in liquid nitrogen. For the postreaction complex, colorless crystals were obtained by soaking the yellow, PLP-loaded crystals in 2 mM **1** for 30 min at 23 $^{\circ}\text{C}$ followed by a 3-s soak in reservoir solution containing 2 mM **1** and 15% PEG 400 and immediately freezing in liquid nitrogen.

Structure Determination. Diffraction data were collected at 100 K on GM/CA-CAT beamline 23ID-D at the Advanced Photon Source in the Argonne National Laboratory (Argonne, IL). Data were integrated and scaled with d*TREK.¹⁹ The structure was solved by molecular replacement using the program Phaser within CCP4 and PDB code 3BV0 as a search model.^{20,21} Initial refinement and model building was done using REFMAC5 and Coot, respectively.^{22,23} Topology and parameter files for 7 were generated using the PRODRG server.²⁴ Final refinement was carried out using Phenix.²⁵ The structures were evaluated using the MOLPROBITY server.²⁶ Images and figures were prepared using PyMOL.^{19,27} Coordinates and structure factors have been deposited at the Protein Data Bank with accession codes of 3TFT (prereaction) and 3TFU (postreaction).

■ ASSOCIATED CONTENT

S Supporting Information. Completed citation for ref 25, characterization data for **2** and all synthetic intermediates, general description of the coupled enzyme assays for the other transaminases evaluated, cell cytotoxicity assays, MS/MS data of PLP-inhibitor adduct, data collection and refinement statistics for BioA structural characterization, figures of pre- and postreaction complex, and ^1H NMR and ^{13}C NMR spectra for all compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

aldri015@umn.edu

Present Addresses

[#]Chemistry Advanced Laboratory' Sheda Science and Technology Complex, P. M. B. 186 Sheda-Kwali, Abuja, FCT, Nigeria

■ ACKNOWLEDGMENT

This research was supported by a grant from the Bill and Melinda Gates foundation and the Wellcome Trust through the Grand Challenges in Global Health Initiative (to Douglas Young, Imperial College), the National Institutes of Health (AI091790 to D.S. and C.C.A.) and the Intramural Research Program of the NIAID, NIH (to C.E.B.). We thank Dr. Lorraine Anderson for assistance in MS/MS experiments, Kathryn Gustafson for assistance in purification and crystallization experiments, and Dr. Anja Meißner for performing cytotoxicity assays. We are grateful for resources from the University of Minnesota Supercomputing Institute.

■ REFERENCES

- (1) (a) World Health Organization. Global tuberculosis control 2010. http://www.who.int/tb/-publications/global_report/2010/en/index.html (last accessed 04/13/11). (b) Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. *Nature* **2011**, 469, 483. (c) Barry, C. E., 3rd; Blanchard, J. S. *Curr. Opin. Chem. Biol.* **2010**, 14, 456.

- (2) Aldrich, C. C.; Boshoff, H. I.; Rimmel, R. P. Antitubercular Agents. In *Burgers Medicinal Chemistry*, 7th ed.; Rotella, D., Abraham, D. J., Eds.; Wiley: New York, 2010; p 713.
- (3) Marquet, A.; Bui, B. T. S.; Florentin, D. *Vit. Horm.* **2001**, *61*, 51.
- (4) (a) Dey, S.; Lane, J. M.; Lee, R. E.; Rubin, E. J.; Sacchetti, J. C. *Biochemistry* **2010**, *49*, 6746. (b) Sassetti, C. M.; Rubin, E. J. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 12989.
- (5) Park, S. W.; Klotzsche, M.; Wilson, D. J.; Boshoff, H. I.; Eoh, H.; Manjunatha, U.; Blumenthal, A.; Rhee, K.; Barry, C. E., 3rd; Aldrich, C. C.; Ehrh, S.; Schnappinger, D. *PLoS Pathog.* **2011**, *7*, e1002264.
- (6) (a) Bhor, V. M.; Dev, S.; Vasanthakumar, G. R.; Kumar, P.; Sinha, S.; Suroliya, A. *J. Biol. Chem.* **2006**, *281*, 25076. (b) Mann, S.; Ploux, O. *Biochim. Biophys. Acta* **2011**, *1814* (11), 1459. (c) Mann, S.; Ploux, O. *FEBS J.* **2006**, *273*, 4778. (d) Mann, S.; Colliandre, L.; Labesse, G.; Ploux, O. *Biochimie* **2009**, *91*, 826. (e) Escalettes, F.; Florentin, D.; Bui, B. T. S.; Lesage, D.; Marquet, A. *J. Am. Chem. Soc.* **1999**, *121*, 3571. (f) Farrar, C. E.; Siu, K. K. W.; Howell, P. L.; Jarrett, J. T. *Biochemistry* **2010**, *49*, 9985.
- (7) Lin, S.; Hanson, R. E.; Cronan, J. E. *Nat. Chem. Biol.* **2010**, *6*, 682.
- (8) (a) Okami, Y.; Kitahara, T.; Hamada, M.; Naganawa, H.; Kondo, S. *J. Antibiot.* **1974**, *27*, 656. (b) Kitahara, T.; Hotta, K.; Yoshida, M.; Okami, Y. *J. Antibiot.* **1975**, *28*, 215. (c) Hotta, K.; Kitahara, T.; Okami, Y. *J. Antibiot.* **1975**, *28*, 222. (d) Poetsch, M.; Zahner, H.; Werner, R. G.; Kern, A.; Jung, G. *J. Antibiot.* **1985**, *38*, 312.
- (9) Mann, S.; Carillon, S.; Breyne, O.; Marquet, A. *Chem.—Eur. J.* **2002**, *8*, 439.
- (10) (a) Sandmark, J.; Mann, S.; Marquet, A.; Schneider, G. *J. Biol. Chem.* **2002**, *277*, 43352. (b) Mann, S.; Florentin, D.; Lesage, D.; Drujon, T.; Ploux, O.; Marquet, A. *Helv. Chim. Acta* **2003**, *86*, 3836. (c) Orisadipe, A.; Boshoff, H. I.; Barry, C. E., 3rd Unpublished results.
- (11) (a) Olson, G. T.; Fu, M.; Lau, S.; Rinehart, K. L.; Silverman, R. B. *J. Am. Chem. Soc.* **1998**, *120*, 2256. (b) Fu, M.; Nikolic, D.; Van Breemen, R. B.; Silverman, R. B. *J. Am. Chem. Soc.* **1999**, *121*, 7751. (c) Fu, M.; Silverman, R. B. *Bioorg. Med. Chem.* **1999**, *7*, 1581. (d) Fu, M.; Silverman, R. B. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 203. (e) Wang, Z.; Yuan, H.; Nikolic, D.; Van Breemen, R. B.; Silverman, R. B. *Biochemistry* **2006**, *45*, 14513. (f) Liu, D.; Pozharski, E.; Lepore, B. W.; Fu, M.; Silverman, R. B.; Petsko, G. A.; Ringe, D. *Biochemistry* **2007**, *46*, 10517. (g) Lepore, B. W.; Liu, D.; Peng, Y.; Fu, M.; Yasuda, C.; Manning, J. M.; Silverman, R. B.; Ringe, D. *Biochemistry* **2010**, *49*, 3138. (h) Liu, D.; Pozharski, E.; Fu, M.; Silverman, R. B.; Ringe, D. *Biochemistry* **2010**, *49*, 10507.
- (12) (a) Anderson, C. E.; Overman, L. E. *J. Am. Chem. Soc.* **2003**, *125*, 12412. er determination protocol: (b) Perez-Fuertes, Y.; Kelly, A. M.; Johnson, A. L.; Arimori, S.; Bull, S. D.; James, T. D. *Org. Lett.* **2006**, *8*, 609.
- (13) Vinylglycine syntheses, (S)-enantiomer: (a) Daniel, R. N.; Melancon, B. J.; Wang, E. A.; Crews, B. C.; Marnett, L. J.; Sulikowski, G. A.; Lindsley, C. W. *J. Org. Chem.* **2009**, *74*, 8852. (b) Berkowitz, D. B.; Maiti, G. *Org. Lett.* **2004**, *6*, 2661. (R)-enantiomer: (c) Hallian, K. O.; Crout, D. H. G.; Errington, W. *J. Chem. Soc., Perkin Trans. 1* **1994**, *24*, 3537.
- (14) (a) Li, H.; Jiang, X.; Ye, Y.; Fan, C.; Romoff, T.; Goodman, M. *Org. Lett.* **1999**, *1*, 91. (b) Jiang, W.; Wanner, J.; Lee, R. J.; Bounaud, P.-Y.; Boger, D. L. *J. Am. Chem. Soc.* **2002**, *124*, 5288.
- (15) Kingsbury, J. S.; Harrity, J. P. A.; Bonitatebus, P. J., Jr.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1999**, *121*, 791.
- (16) Wilson, D. J.; Shi, C.; Duckworth, B. P.; Muretta, J. M.; Manjunatha, U.; Sham, Y. Y.; Thomas, D. D.; Aldrich, C. C. *Anal. Biochem.* **2011**, *416*, 27.
- (17) Copeland, R. A. Irreversible Enzyme Inactivators. *Evaluation of Enzyme Inhibitors in Drug Discovery*; Wiley & Sons: Hoboken, N.J., 2005; p 214.
- (18) Garcia-Fandino, R.; Aldegunde, M. J.; Codesido, E. M.; Castedo, L.; Granja, J. R. *J. Org. Chem.* **2005**, *70*, 8281.
- (19) Pflugrath, J. W. *Acta Crystallogr., D: Biol. Crystallogr.* **1999**, *55*, 1718.
- (20) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. *J. Appl. Crystallogr.* **2007**, *40*, 658.
- (21) Collaborative Computational Project, Number 4. *Acta Crystallogr., D: Biol. Crystallogr.* **1994**, *50*, 760.
- (22) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. *Acta Crystallogr., D: Biol. Crystallogr.* **1997**, *53*, 240.
- (23) Emsley, P.; Cowtan, K. *Acta Crystallogr., D: Biol. Crystallogr.* **2004**, *60*, 2126.
- (24) Schuttelkopf, A. W.; van Aalten, D. M. *Acta Crystallogr., D: Biol. Crystallogr.* **2004**, *60*, 1355.
- (25) Adams, P. D.; et al. *Acta Crystallogr., D: Biol. Crystallogr.* **2010**, *66*, 213.
- (26) Davis, I. W.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. *Nucleic Acids Res.* **2004**, *32*, W615.
- (27) DeLano, W. L. *The PyMOL molecular graphics system*; DeLano Scientific: Palo Alto, CA, 2002.
- (28) Cook, M. J.; Katritzky, A. R.; Linda, P.; Tack, R. D. *Chem. Commun.* **1971**, 510.
- (29) (a) Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. *Nat. Rev. Drug Discovery* **2011**, *10*, 307. (b) Lu, H.; Tonge, P. J. *Curr. Opin. Chem. Biol.* **2010**, *14*, 467.
- (30) (a) Cerqueira, N. M. F. S. A.; Fernandes, P. A.; Ramos, M. J. *J. Chem. Theory Comput.* **2011**, *7*, 1356–1368. (b) Oliveira, E. F. O.; Cerqueira, N. M. F. S. A.; Fernandes, P. A.; Ramos, M. J. *J. Am. Chem. Soc.* **2011**, *133* (39), 15496.
- (31) Nanavati, S. M.; Silverman, R. B. *J. Med. Chem.* **1989**, *32*, 2413.
- (32) Lowther, J.; Yard, B. A.; Johnson, K. A.; Carter, L. G.; Bhat, V. T.; Raman, M. C.; Clarke, D. J.; Ramakers, B.; McMahon, S. A.; Naismith, J. H.; Campopiano, D. J. *Mol. Biosyst.* **2010**, *6*, 1682.
- (33) (a) Bird, C. W. *Tetrahedron* **1985**, *41*, 1409. (b) Bird, C. W. *Tetrahedron* **1986**, *42*, 89.
- (34) Nishino, T.; Murao, S.; Wada, H. *J. Biochem.* **1984**, *95*, 1283.